美国儿童抗中性粒细胞胞质抗体相关血管炎住院治疗差异
该回顾性队列研究利用2004-2014年47家三级儿童医院的行政账单数据库,分析393名AAV住院患儿的治疗模式。结果显示环磷酰胺使用占57%、利妥昔单抗21%、血浆置换22%,利妥昔单抗使用随时间增加而环磷酰胺减少,各医院间治疗使用差异显著。
要点
- 儿童严重AAV治疗正从环磷酰胺向利妥昔单抗转变。
- 透析、机械通气和延长住院在患儿中仍常见。
- 血浆置换使用在医院间差异尤为显著。
核心结论
- 儿童严重AAV的治疗正从环磷酰胺向利妥昔单抗转变,血浆置换使用高度可变。
研究设计与样本
- 回顾性队列研究,利用2004-2014年47家三级儿童医院的行政与账单数据库,纳入393名AAV住院患儿。
主要发现
- 中位指数入院年龄14.6岁,61%为女性。
- 16%的患儿需要透析,17%需要机械通气,中位住院时间9天。
- 57%的患儿接受环磷酰胺,21%接受利妥昔单抗,10%同时接受两者,22%接受血浆置换。
- 机械通气与接受环磷酰胺和血浆置换相关,但与利妥昔单抗无关。
- 研究期间利妥昔单抗使用呈增加趋势(P < 0.05),环磷酰胺使用呈减少趋势(P < 0.05)。
临床怎么用
- 临床医生应知晓儿童严重AAV治疗模式正转向利妥昔单抗。
- 血浆置换使用差异大,需关注其适应证选择的机构间变异。
局限性
- 基于行政和账单数据库,治疗识别依赖计费数据可能不准确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: There are few reports on the treatment of antineutrophil cytoplasmic antibody-associated vasculitis (AAV) in children. This study characterizes the use of cyclophosphamide, rituximab, and plasma exchange in children hospitalized with AAV in the US. METHODS: We conducted a retrospective cohort study of children hospitalized with AAV from 2004-2014 utilizing an administrative and billing database from 47 tertiary care pediatric hospitals. All patients had an International Classification of Diseases, Ninth Revision, Clinical Modification discharge code of 446.4 and ≥1 charge for glucocorticoids. Treatment receipt was determined using billing data. Mixed-effects logistic regression was used to evaluate factors associated with the likelihood of receipt of each of the 3 treatments. RESULTS: During the 11-year study period there were 1,290 admissions for 393 children. The median age at index admission was 14.6 years, and 61% were female. Dialysis or mechanical ventilation was required by 16% and 17% of the children, respectively. The median length of stay was 9 days. The percentages of children receiving cyclophosphamide, rituximab, or both were 57%, 21%, and 10%, respectively, and 22% received plasma exchange. Mechanical ventilation was associated with the receipt of cyclophosphamide and plasma exchange, but not rituximab. There was an increasing trend in the use of rituximab over time during the study period (P < 0.05), and a decreasing trend in the use of cyclophosphamide (P < 0.05). Treatment use varied significantly between hospitals, especially for plasma exchange. CONCLUSION: The treatment of children with severe AAV is shifting from cyclophosphamide to rituximab, and their need for dialysis, mechanical ventilation, and prolonged hospitalization remains common. Use of plasma exchange is highly variable.
引用
- James KE, Xiao R, Merkel PA, et al. Variation in the Treatment of Children Hospitalized With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in the US. Arthritis Care Res (Hoboken). 2017. PMID: 27813340. doi:10.1002/acr.23142
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。